A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2022-05-22
Adverse events
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-08-29 (study day 89); relationship: N
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-09-16 (study day 107); relationship: not assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-09-21 (study day 112); relationship: not assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-01-30 (study day 243); relationship: N
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-02-14 (study day 258); relationship: not assessed
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-02-16 (study day 260); relationship: not assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-10-04 (study day 490); relationship: not assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-12-15 (study day 562); relationship: not assessed
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-27 (study day 574); relationship: not assessed; serious criteria: hospitalization
Data queries
No data queries.